XML 36 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements of Cash Flows (USD $)
 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Cash flows from operating activities:    
Net loss $ (19,476,782) $ (25,732,707)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 730,504 759,527
Stock-based compensation 2,033,228 2,227,145
Amortization of debt discount and issuance costs 509,069  
Gain on disposal of fixed assets (34,946)  
Change in fair value of warrant liability (425,570) 9,974,685
Changes in operating assets and liabilities:    
Accrued interest and other receivables (364,940) 19,432
Trade receivables 57,569 (40,584)
Prepaid and other current assets 782,745 170,667
Other assets, non-current (52,474) 32,926
Accounts payable and accrued expenses 499,935 (1,613,123)
Accrued wind-down expenses (1,102,762) (817,110)
Deferred revenue (19,146) (665)
Deferred rent 431,390 69,997
Net cash used in operating activities (16,432,180) (14,949,810)
Cash flows from investing activities:    
Purchase of marketable securities (527,967) (8,109,933)
Proceeds from the maturity of marketable securities 14,430,000 5,362,000
Purchases of property, plant and equipment (4,556,406) (19,729)
Proceeds from sale of property, plant and equipment 38,500  
Acquisition of other assets (100,000)  
Net cash provided by (used in) investing activities 9,284,127 (2,767,662)
Cash flows from financing activities:    
Proceeds from issuance of common stock, net of issuance costs 6,115,442 16,196,587
Proceeds from the exercise of stock options 2,809  
Proceeds from the exercise of warrants, net of issuance costs 460,097 4,153,584
Proceeds from loan payable, net of issuance costs 13,558,358  
Payments related to net share issuance of stock based awards (342,366) (59,090)
Repayment of capital lease obligations (7,302) (18,521)
Repayment of bonds payable (152,500) (141,250)
Net cash provided by financing activities 19,634,538 20,131,310
Increase in cash and cash equivalents 12,486,485 2,413,838
Effects of foreign exchange rate changes on cash (2,467) (12,411)
Cash and cash equivalents, beginning of period 8,471,275 13,311,261
Cash and cash equivalents, end of period 20,955,293 15,712,688
Supplemental disclosure of cash flow information:    
Interest paid 271,054 40,114
Supplemental schedule of non-cash investing and financing activities:    
Fair value of 329,131 shares issued as consideration under an equity financing agreement 600,006 [1]  
Stock issued for an option agreement   50,000 [2]
Equipment acquired under a capital lease $ 43,600 [3] $ 21,721 [3]
[1] In June 2013, we entered into an agreement with an institutional investor, under which we have the right to sell up to $30.0 million of common stock to the institutional investor. In consideration for entering into the agreement, we issued 329,131 shares of our common stock to the institutional investor. We will not receive any cash proceeds from the issuance of these 329,131 shares. All shares sold or to be sold under this agreement are offered under our shelf registration statement previously filed with, and declared effective by, the SEC. In October 2013, we terminated the agreement without any cost or penalty.
[2] In September 2012, we issued 24,753 shares of restricted common stock under the terms of an agreement with a developer of biological materials in return for certain product rights including an exclusive right of first offer to commercialize the developer's products as may be developed on or before April 18, 2017.
[3] Represents the present value of future minimum capital lease payments for equipment leased.